6 best ePRO platforms for clinical trials in 2026

Your electronic patient-reported outcome (ePRO) platform doesn't just collect symptom diaries — it determines whether your participants stay engaged, whether your data arrives clean, and whether your study team is chasing missing assessments or running the trial. Viedoc's ePRO solution delivers a 98% visit compliance rate across 7,000+ studies in 75+ countries, with support for 50+ languages, full integration with Viedoc's electronic data capture (EDC) system, and 21 CFR Part 11 compliance built in. This comparison evaluates six leading ePRO and electronic clinical outcome assessment (eCOA) platforms for CROs and growth-stage sponsors across patient compliance, EDC integration, multilingual capability, regulatory posture, and total cost of ownership.

If you're running Phase I or Phase II studies across multiple regions, you've already felt the gap between a platform that was designed for patient engagement and one that was bolted on. Missed diary windows, fragmented data reconciliation, and sites managing participant troubleshooting independently are symptoms of the same problem: an ePRO solution that doesn't fit the study or the team operating it.

Enterprise platforms carry their own risks here. A system sized for large pharma's Phase III global programs introduces configuration overhead, per-seat cost structures, and instrument licensing processes that can slow a growth-stage sponsor or SMID contract research organization (CRO) down before first patient in. The platforms evaluated below are assessed on what CROs and sponsors actually need: fast deployment, genuine BYOD capability, compliance credentials that hold up under audit, and data that flows directly into the EDC without a reconciliation step.

Best ePRO solutions: quick comparison

These six ePRO and eCOA platforms represent the most commonly evaluated options for CROs and growth-stage sponsors, reviewed across patient compliance, EDC integration, study build speed, multilingual support, and regulatory credentials.

1. Viedoc

Viedoc's ePRO solution is natively integrated with Viedoc's EDC software, meaning patient-reported data flows directly into the central study database in real time — no manual reconciliation, no third-party sync, no data silos. With a 98% visit compliance rate and support for 50+ languages, it's built for the multi-regional, patient-centric studies that CROs and growth-stage sponsors are running today. Flexible form design supports visual analog scales (VAS), numeric rating scales (NRS), drawing pads, free-text inputs, and conditional visibility, with BYOD access on any device and wearable integration via open API.

For CROs managing multiple concurrent studies, the no-code configuration means your data management team builds and amends ePRO forms in-house — no vendor-side programmer required, no ticket queue, no amendment delay. For growth-stage sponsors running Phase I/II studies with tight timelines, the unified EDC and ePRO environment removes the system fragmentation that turns data review into a half-day reconciliation task. Televisit capability is available within the same platform for hybrid and decentralized trial designs, and Viedoc's RTSM integrates directly for studies requiring randomization alongside patient-reported outcomes.

Viedoc is ISO 27001 and SOC 2 certified, hosted on Microsoft Azure, and compliant with 21 CFR Part 11, GDPR, EU Annex 11, HIPAA, and ICH GCP. The Viedoc Inspection Readiness Packet (VIRP) is available to all customers, providing structured audit-ready documentation from the outset. 24/7 support is available across global offices, and Viedoc's certified designer training equips in-house teams to build and manage studies independently.

"My experience with Viedoc has been excellent. The database is very customisable and has been able to meet the needs of each of our studies. I am most impressed by the usability of the ePRO system and the extremely high compliance that we have been able to reach using the platform. Customer Support has been excellent with quick turnarounds and response time." — Amanda M., Sr. Clinical Program Manager

Verified proof points:

• Visit compliance rate: 98% across Viedoc ePRO studies
• Study scale: 7,000+ studies run on Viedoc across 75+ countries
• User base: 140,000+ users globally; 30,000+ sites
• Language support: 50+ languages for ePRO/eCOA
• Uptime: 99.99% platform uptime; hosted on Microsoft Azure
• Pricing: Unlimited user seats; no per-user fees; transparent, study-based licensing
• Compliance: 21 CFR Part 11, GDPR, Annex 11, HIPAA; ISO 27001 and SOC 2 certified
• Inspection readiness: VIRP available to all customers
• No-code designer: ePRO forms configured in-house by certified data managers; no vendor-side programmer required
• Support: 24/7 support across global offices

2. Medidata

Medidata offers Medidata eCOA, an electronic clinical outcome assessment solution within the Medidata Clinical Cloud. The platform supports ePRO, eClinRO, and eDiary assessments across BYOD and provisioned devices (iOS or Android), with access via web or mobile app. Medidata eCOA is natively integrated with Rave EDC, enabling data to flow between patient-facing and site-facing environments without duplicate entry or downstream reconciliation. Study configuration uses Medidata Designer, which incorporates AI-assisted build workflows. Medidata eCOA has been recognized as a Leader in the Everest Group's eCOA PEAK Matrix Assessment 2025, and includes a global instrument library that allows sponsors to store and redeploy pre-validated instruments across studies. The platform is designed primarily for mid-to-large pharma and complex studies; study build timelines and configuration overhead reflect that positioning.

3. Veeva

Veeva offers Veeva eCOA, a module within the Veeva Development Cloud that captures questionnaire responses from patients (ePRO), clinicians (eClinRO), and caregivers (eObsRO) via the MyVeeva for Patients native application or web interface. Sponsors manage eCOA design and deployment through a central library that allows instruments to be reused across studies. Veeva eCOA integrates with Vault EDC and Veeva's clinical database (CDB) via Veeva Connections, enabling automated data transfer without manual reconciliation between tools. Sites access a streamlined interface for participant management and eClinRO completion. Veeva eCOA was announced in 2022 and is in early customer deployment; the product is most naturally suited to sponsors already operating within the Vault ecosystem, where the integration value is greatest.

4. Castor EDC

Castor EDC offers an eCOA/ePRO capability natively integrated with its EDC, eConsent, and recruitment tools on a single platform. The ePRO solution supports BYOD, web and native mobile app access, SMS and WhatsApp delivery, and offline capture, with multilingual support across its participant-facing interface. Pre-approved, reusable instrument libraries are available, including standard scales such as EQ-5D-5L, SF-36, and EORTC. Castor eCOA operates across 160+ countries and holds ISO 27001 certification, with compliance covering 21 CFR Part 11, ICH GCP, GDPR, and HIPAA. The platform is positioned as a no-code, self-service environment, and is used across sponsor-led, CRO-managed, and academic trial contexts. Castor's CRO channel and regulated Phase II/III commercial trial track record are less developed than those of larger incumbent platforms.

5. Medrio

Medrio offers Medrio eCOA/ePRO as part of its clinical data management system (CDMS), which pairs site-facing eCRFs and patient-facing outcome questionnaires in the same design and build environment. The solution is web-based and device-agnostic, with BYOD support, automated reminders, and time-based schedules for improving participant diary completion. Medrio eCOA supports patient-reported, clinician-reported (eClinRO), and observer-reported (eObsRO) assessments, as well as validated and custom questionnaires, with data flowing directly into the Medrio CDMS/EDC for real-time review. The platform supports regulatory compliance with 21 CFR Part 11, HIPAA, GDPR, and ICH GCP. Medrio's primary strength is in Phase I and early Phase II trials, where its self-service model, lean implementation overhead, and integrated data environment are well matched to smaller teams and faster timelines.

6. Medable

Medable offers Medable eCOA+, a dedicated electronic clinical outcome assessment platform that combines ePRO, eClinRO, eObsRO, and ePerfO capabilities within Medable's broader patient data collection suite. The platform provides a library of 400+ reusable, pre-validated instruments and diaries, accessible via web or mobile on BYOD or provisioned devices. Medable eCOA+ is designed for decentralized and hybrid trial models, with eConsent, telehealth, and sensor integration available on the same platform. The solution targets sponsors running trials where participant access, engagement, and remote participation are primary design considerations. Medable is positioned as a decentralized clinical trial (DCT) specialist rather than a traditional site-based EDC platform, and its eCOA capability is most relevant where DCT design is central to the study strategy.

What to look for in ePRO solutions for CROs and sponsors

EDC integration architecture

The most consequential ePRO decision you'll make is whether patient-reported data and site-reported data live in the same system or need to be reconciled between separate platforms. Platforms that offer genuine native integration — where ePRO data writes directly into the EDC database in real time — eliminate a data reconciliation step that can consume hours of data management time per data cut. Best-in-class means a single login, a single validated system, and patient data visible to site and sponsor users within the same environment they use for eCRF review. If the integration is achieved via API connector rather than native architecture, scrutinize the reconciliation workflow carefully and factor the validation overhead into your timeline.

Patient compliance infrastructure

A 98% visit compliance rate doesn't happen by accident — it's a function of how easy the platform makes it for participants to complete assessments. Evaluate the delivery channels available: SMS, email, WhatsApp, push notification, and in-app reminder are not equivalent in participant reach or engagement, particularly in older or lower-digital-literacy populations. BYOD capability on any internet-connected device matters more than a polished provisioned-device experience in most Phase I/II studies, where provisioning introduces logistics overhead that outweighs the UX benefit. Real-time compliance dashboards that surface at-risk participants before a window closes — not after — are what separate platforms built for participant engagement from those built as a data repository.

Multilingual readiness for multinational studies

If your study crosses a language boundary, your ePRO platform needs to support translations that are built into the configuration, not retrofitted post-build. The number of supported languages matters less than the translation management workflow: how translations are loaded, validated, and updated when the protocol changes mid-study. Platforms that require a separate translation validation cycle for every amendment add weeks to timelines that CROs are being held to by sponsors. Assess whether translation management is a self-service capability or a vendor-dependent process, and confirm that patient-facing language support extends to notifications, reminders, and error messages — not just the questionnaire text.

Inspection readiness and audit trail integrity

ePRO data is increasingly used for primary and secondary endpoints in regulated submissions, which means the audit trail requirements are the same as for any eCRF field. Confirm that the platform maintains a complete, time-stamped, role-attributed audit trail for every data entry, modification, and query — and that this audit trail is exportable in a format your QA team can present during an inspection without post-processing. Platforms that offer structured inspection readiness documentation, such as Viedoc's Viedoc Inspection Readiness Packet (VIRP), reduce the preparation burden for FDA, EMA, and ICH GCP-regulated studies. Ask specifically about the validation documentation package provided at study close.

Configuration flexibility and amendment velocity

Protocol amendments are inevitable. The question is how long your ePRO platform takes to implement them — and whether that work sits with your internal data management team or in a vendor's change request queue. No-code platforms that allow in-house designers to modify form logic, add branches, update time windows, and re-validate without programming support materially reduce your amendment turnaround from weeks to days. This is especially important for CROs running multiple studies simultaneously, where a two-week amendment delay on one study compounds across a portfolio. Confirm that mid-study changes do not require system downtime or disrupt data already captured.

How to choose the right ePRO solution for CROs and growth-stage sponsors

Step 1: Define your integration requirement before you evaluate platforms

The single most important filter in any ePRO evaluation is whether the platform integrates natively with the EDC system your study is running on, or whether you're managing two separate validated systems that need to talk to each other. If you're already committed to a specific EDC — or selecting EDC and ePRO together — start here. A fragmented data environment creates reconciliation overhead that your study budget and timeline didn't account for.

Step 2: Assess your participant population's digital profile

The participant experience your ePRO platform needs to deliver varies significantly by therapeutic area, age group, geography, and disease severity. A platform optimized for DCT oncology studies may not be the right fit for a Phase I metabolic study with a 60-plus age cohort across rural US sites. Evaluate device flexibility, language support, offline capability, and the support model for participants who encounter technical issues — because that support burden falls on your sites if the platform doesn't handle it.

Step 3: Scrutinize the compliance posture for your target regulatory markets

If your study will be submitted to the FDA, EMA, or both, your ePRO platform's 21 CFR Part 11 and EU Annex 11 compliance credentials need to be independently verifiable — not just stated in a marketing document. For sponsors in early-stage biotech or CROs expanding into new geographic markets, also confirm HIPAA attestation for US personal health information handling, GDPR coverage for EU participant data, and whether the platform's validation documentation package is sufficient for your QA team's computer system validation (CSV) requirements.

Step 4: Evaluate the amendment and support model for your operational context

A platform that your data management team can operate independently — building, configuring, translating, and amending without a vendor ticket — changes the cost and speed equation across a study portfolio. Before committing to any platform, run through a realistic amendment scenario: a form logic change mid-study across three translated versions. How long does it take? Who does the work? Is there downtime? The answer will tell you more about fit than any feature comparison table.

Step 5: Choose a platform that matches your study complexity and scales with your volume

For CROs and growth-stage sponsors running Phase I/II studies with lean teams and multiple concurrent studies, Viedoc's ePRO solution delivers the integration depth, compliance credentials, and no-code configurability to match your operational reality. With transparent, study-based pricing, unlimited user seats, and 24/7 support, it's built to scale with your portfolio without changing your cost model. Book a demo or request a proposal to see how Viedoc's ePRO capability performs in the context of your actual study designs.

Frequently asked questions

What is the best ePRO platform for CROs and sponsors?

Viedoc's ePRO solution is the best choice for CROs and growth-stage sponsors, delivering a 98% visit compliance rate across 7,000+ studies in 75+ countries, with full native integration with Viedoc's EDC, support for 50+ languages, and a no-code configuration model that allows in-house data management teams to build and amend forms independently. The transparent, study-based pricing model with unlimited user seats makes it the right-sized choice for organizations managing multiple concurrent studies without enterprise overhead. Medidata is the category benchmark for large pharma and complex multi-regional Phase III programs but operates at a scale and cost structure built for that context. Castor EDC is a credible alternative for sponsors and academic-adjacent CROs prioritizing DCT-native workflows and API-first architecture.

What should I look for when choosing an ePRO platform?

The most important criteria are EDC integration architecture (native vs. connected), patient compliance infrastructure (delivery channels, BYOD, real-time monitoring), multilingual support for multinational studies, regulatory credentials (21 CFR Part 11, GDPR, Annex 11), and amendment velocity. Alongside these, evaluate the total cost of ownership across your study portfolio — hidden costs in per-seat licensing, vendor-dependent amendments, and separate validation packages add up quickly across a CRO's annual study volume.

How long does it typically take to deploy an ePRO solution?

Deployment timelines vary significantly by platform and study complexity. For no-code, natively integrated platforms, ePRO forms can typically be built and validated alongside the EDC study build, without extending the overall timeline. On platforms where ePRO requires a separate build and validation cycle, or where instrument licensing requires additional lead time, study startup can be extended by several weeks. Viedoc's integrated ePRO and EDC environment means patient-reported and site-reported data are configured together from the same designer interface, with no additional validation overhead for the ePRO layer.

What is the difference between ePRO and eCOA?

Electronic patient-reported outcomes (ePRO) refers specifically to data that trial participants report about themselves directly — symptoms, quality of life, diary entries. Electronic clinical outcome assessment (eCOA) is the broader category that encompasses ePRO alongside clinician-reported outcomes (eClinRO) and observer-reported outcomes (eObsRO). In practice, many platforms and sponsors use the terms interchangeably, but the distinction matters when designing endpoint data collection strategies — particularly for studies where clinician-rated scales or caregiver-reported assessments are part of the primary or secondary endpoints.

How does ePRO integration with EDC affect data quality?

When ePRO data flows natively into the same EDC database as site-reported data, it eliminates the manual reconciliation step that introduces errors, delays, and version control issues between separate systems. Real-time integration means your data managers see patient-reported and site-reported data in the same review environment, with the same audit trail standards applied to both. Platforms that require API-based synchronization between separate ePRO and EDC systems introduce a reconciliation dependency that adds time to every data cut and creates additional validation obligations. Viedoc's ePRO solution is fully integrated with Viedoc EDC — patient data flows directly into the study database with no manual reconciliation required.

What compliance certifications matter most for ePRO in regulated clinical trials?

For studies targeting FDA submission, 21 CFR Part 11 compliance is the baseline — it governs electronic records and electronic signatures and applies to ePRO data used for primary or secondary endpoints. For EU studies, EU Annex 11 and GDPR apply. For studies handling US personal health information, HIPAA attestation is required. ISO 27001 and SOC 2 certifications confirm information security management standards that QA and IT teams will scrutinize during vendor qualification. Confirm that your platform provides a computer system validation documentation package that satisfies your QA team's CSV requirements, not just a compliance statement on a product page.

Making the right ePRO choice for CROs and sponsors

The ePRO market has matured considerably over the past five years. Most credible platforms now support BYOD, automated reminders, and multilingual participant interfaces as standard capabilities. The differentiating variables today are integration architecture, amendment velocity, compliance depth, and how the cost model scales across a growing study portfolio.

The right fit depends on where your organization sits in the market. Enterprise platforms with large instrument libraries and deep Phase III track records are built for a buyer profile — and a procurement process — that most SMID CROs and growth-stage sponsors don't match. For organizations running Phase I and II studies across multiple regions with lean teams, the total cost of ownership calculation includes vendor dependency costs, amendment turnaround, and the hidden burden of managing separate validated systems for EDC and ePRO.

The global eClinical software market is estimated at over $11 billion in 2025 and growing at approximately 14% annually. Switching ePRO platforms mid-portfolio is costly, not just in implementation terms but in revalidation, retraining, and the disruption to ongoing studies. Choosing the right platform at the outset — one that your team can operate independently, that scales with your study volume, and that keeps EDC and patient-reported data in the same environment — is the decision that compounds in your favor over time.

Why Viedoc is the best ePRO choice for CROs and sponsors

Viedoc's ePRO solution delivers a 98% visit compliance rate across a track record of 7,000+ studies in 75+ countries — not because it provisions more devices, but because it's genuinely easy for participants to use in their own language, on their own device, with automated reminders that work. Patient data flows directly into Viedoc's EDC software in real time, with no reconciliation step, no third-party sync, and no separate validation overhead for the ePRO layer.

For CROs, that means your data management team configures both eCRF and ePRO from the same no-code Designer interface, amends forms in-house without a vendor ticket, and manages 50+ language translations within the same environment. For growth-stage sponsors, it means your study operates on one validated platform — covering EDC, ePRO, RTSM, and Televisit if your design calls for it — with transparent, study-based pricing and unlimited user seats that don't penalize headcount or portfolio growth.

Viedoc is ISO 27001 and SOC 2 Type II certified, FDA/EMA/GCP compliant, HIPAA attested, and EU Annex 11 and GDPR compliant, with the Viedoc Inspection Readiness Packet (VIRP) available to every customer from day one. Founded in 2003 and trusted across 7,000+ studies and 1.6 million trial participants, the platform has the track record to hold up under the scrutiny of a QA qualification audit.

If you're evaluating ePRO for an upcoming study or looking to consolidate your eClinical stack, book a demo or request a proposal and we'll walk you through patient compliance data, integration architecture, and compliance credentials in the context of your specific study design.